RxDoctor Payments Data

Samantha Warkentien

Psychiatric/Mental Health · Springfield, MONPI 1851769350

Payments from drug & device makers

$1,422in general payments, 2019–2025

Across 56 payments — averaging $25.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$834
  • Otsuka America Pharmaceutical, Inc.$236
  • Axsome Therapeutics, Inc.$91
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$67
  • Takeda Pharmaceuticals U.S.A., Inc.$62
  • Neurocrine Biosciences, Inc.$60
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$1,37397%
  • Education$493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,422 in reported general payments places this provider in the 60th percentile of 565 psychiatric/mental health providers in Missouri.

See all psychiatric/mental health providers in Missouri

Medicare billing

Part B allowed, 2024
$18,036
Medicare patients
146
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate89$325,734
AustedoDeutetrabenazine24$127,624
TrintellixVortioxetine Hydrobromide82$37,680
VraylarCariprazine Hcl17$24,534
RexultiBrexpiprazole15$22,465
AuvelityDextromethorphan Hbr/Bupropion18$21,336
CaplytaLumateperone Tosylate11$18,229
EliquisApixaban17$10,591
Paliperidone ErPaliperidone21$10,267
Sucralfate32$5,807
Aripiprazole37$2,887
Divalproex Sodium ErDivalproex Sodium35$2,833
Gabapentin143$2,326
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc20$2,067
Olanzapine69$1,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$62$37,68082 claims
AbbVieVraylar$834$24,53417 claims
Otsuka America Pharmaceutical, Inc.Rexulti$236$22,46515 claims
Axsome Therapeutics, Inc.Auvelity$91$21,33618 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$67$18,22911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 565 psychiatric/mental health providers in Missouri.

Other psychiatric/mental health in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →